BOSTON, Mass. ( TheStreet) --The dog days of August are here. Nothing of much importance is going on. It's hot and humid in Boston, and I'm getting ready for a much-needed vacation. The rest will come in handy because the biotech sector gets back to business in September.

To get you ready, I've put together a calendar of September biotech events. Enjoy.

Aug. 24
U.S. Food and Drug Administration's responds to Cell Therapeutics' ( CTIC - Get Report) priority review request for pixantrone as a treatment for non-Hodgkin's lymphoma.

Sept. 1
The Oncologic Drug Advisory Committee of the Food and Drug Administration meets to review Genzyme's ( GENZ) Clolar and Vion Pharmaceuticals' ( VION.OB) Onrigin, both as a treatment for acute myeloid leukemia.

Sept. 2
The same FDA advisory committee meets to review Allos Therapeutics' ( ALTH) pralatrexate for peripheral T-cell lymphoma.
FDA approval decision date for Endo Pharmaceuticals' ( ENDP - Get Report) Nebido, a long-acting testosterone replacement therapy.

Sept. 7
FDA approval decision date for Spectrum Pharmaceuticals' ( SPPI - Get Report) Zevalin, a drug for non-Hodgkin's lymphoma.

Sept. 9-10
Robert W. Baird Small Cap Health Care Conference

Sept. 9-11
Thomas Weisel Partners Healthcare Conference (Boston) and the Rodman & Renshaw 11th Annual Healthcare Conference (New York City)

Sept. 11-15
American Society for Bone and Mineral Research (ASBMR)

Sept. 12-15
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Sept. 13-15
American College of Clinical Pharmacology (ACCP)

Sept. 14-15
Morgan Stanley Healthcare Unplugged Conference

Sept. 16
The 16th Annual NewsMakers in the Biotech Industry, sponsored by BioCentury.
The Arthritis Drugs Advisory Committee of the FDA will review Auxilium Pharmaceutical's ( AUXL) Xiaflex for advanced Dupuytren's disease, a condition in which the tendons of the hand that help move the fingers of the hand become thickened and scarred.
FDA approval decision date for Theravance's ( THRX) antibiotic Telavancin.

Sept. 20-24
European Cancer Organization and European Society for Medical Oncology Multidisciplinary Congress

Sept. 21-23
UBS Global Life Science Conference

Sept. 24
FDA approval decision date for Eurand Pharmaceuticals' ( EURX) Zenpep, a drug for pancreatic insufficiency.
FDA approval decision date for Allos Therapeutics' Pralatrexate for peripheral T-cell lymphoma.
Dendreon ( DNDN) analyst day

Sept. 27-Oct. 1
European Association for the Study of Diabetes (EASD)

Important clinical trials with potential data readouts in September:

Company: Osiris Therapeutics ( OSIR)
Drug/indication: Prochymal for graft-vs.-host disease

Company: Acadia Pharmaceuticals ( ACAD)
Drug/indication: pimavanserin for Parkinson's disease pychosis (PDP)

Company: Arena Pharmaceuticals ( ARNA)
Drug/indication: lorcaserin for obesity

Company: Chelsea Therapeutics ( CHTP)
Drug/indication: droxidopa for orthostatic hypotension

-- Written by Adam Feuerstein in Boston

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.